Loading stock data…
Ovid Therapeutics Inc. (OVID)
$2.75-0.05 (-1.79%)
Market ClosedLast close Sep 8
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ovid Therapeutics Inc. in the Healthcare sector is trading at $2.75 with a market capitalization of $537M. Wall Street consensus targets $5.80 (9 analysts), implying a +111.1% move over the next 12 months. The stock is currently near its 52-week high of $3.10, remaining 25.0% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +111.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $718,000↑ | $132,000↓ | $6.27M↑ | $130,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$17.85M↓ | -$12.29M↑ | -$12.52M↓ | -$5.07M↑ | -$12.55M |
| Net Income | -$16.99M↓ | $9.66M↑ | -$12.16M↓ | -$4.68M↑ | -$10.23M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a G...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$537.07M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-16.43%
Volume
Today's trading volume
1.15M
Recent News
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +20.00% and +388.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Outlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
Lexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -88.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.